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Abstract 
Stroke is the most common cause of permanent disability, the second most common cause of 
dementia, and the fourth most common cause of death in the Western world. Recently, based 
on positive multicenter randomized clinical trials, endovascular therapy (EVT) for acute 
stroke has undergone a revolution. Routine mechanical thrombectomy in addition to 
intravenous thrombolysis has been shown to provide excellent outcomes for patients with 
proximal anterior circulation occlusions. This procedure reduces disability and benefits are 
seen across a wide range of age and initial stroke severity. Important features that affect 
treatment decisions include time of presentation, the patient’s clinical status, imaging 
characteristics, and lab tests. Under optimal conditions, it should be available to patients 24/7, 
similar to systems offering prompt percutaneous coronary interventions to patients with acute 
ST-segment elevation myocardial infarctions.  
 
 
 
Introduction 
Stroke is the most common cause of permanent disability, the second most common cause of 
dementia, and the fourth most common cause of death in the Western world1. The World 
Health Organization estimates that 5.7 million people die from stroke each year. Each year 
about 795,000 people in the United States and 1 million people in the European Union 
experience a new or recurrent stroke (ischemic or hemorrhagic). The majority (>80%) of 
acute strokes are ischemic. The patients who survive are often burdened with exorbitant 
rehabilitation costs, lost wages and productivity, limitations in their daily social activity, and 
significant residual disability2. Given that the aging population of the world is increasing in 
size, the statistics of stroke incidence and prevalence are likely to also climb proportionately.  
 
The drug therapy for acute ischemic stroke is thrombolysis with recombinant tissue 
plasminogen activator (t-PA), which has been shown in clinical trials to be effective3. 
However, among occlusions of large proximal vessels resulting in severe strokes, 
recanalization rates are reduced, resulting in an overall poor prognosis. For many years the 
concept of catheter directed delivery of thrombolytic medications was investigated.  The 
hypothesis behind this treatment paradigm was that delivering thrombolytics directly to the 
site of arterial occlusion may provide faster vessel recanalization with fewer bleeding 
complications due to less thrombolytic drug use.  The goal intra-arterial thrombolysis (IAT) 
was to decrease the level of disability caused by the stroke and perhaps increase the 
thrombolytic window beyond the 3 hours studied in the original NINDS trial with IV tPA 4. 
The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) randomized controlled 
study provided pilot data supporting this hypothesis 5.  However a recent meta-analysis 
comparing IAT to supportive medical therapy as well as to IV tPA failed to demonstrate 
compelling benefit 6.   
Recently, based on positive multicenter randomized clinical trials, endovascular therapy 
(EVT) underwent a revolution7. Endovascular treatments increase the chance of successful 
and rapid recanalization. In recent years, much effort has been made to develop new 
revascularization devices that provide faster and higher recanalization rates in order to 
generate a better clinical outcome for patients8. Several randomized clinical trials have 
assessed this combined approach. Between December 2014 and August 2016, six randomized, 
controlled trials and individual patient data meta-analysis demonstrated that thrombectomy 
combined with standard medical treatment is more effective than standard medical treatment 
alone for severe acute stroke caused by large-vessel occlusion in anterior circulation7,9-14. 
International guidelines have been recently updated to include recommendation of EVT when 
possible15.  
 
Background and Evidence 
Recent randomized clinical trials  
Recently, the Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute 
Ischemic Stroke in the Netherlands (MR CLEAN) demonstrated a clear overall benefit of 
adding EVT to standard care (including intravenous thrombolysis) in patients with acute 
ischemic stroke caused by proximal arterial occlusion of the anterior circulation, if 
administered within 6 hours from symptom onset 7. 
After publication of the results of MR CLEAN five subsequent trials ESCAPE (Endovascular 
Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on 
Minimizing CT to Recanalization Times)13, EXTEND-IA (Extending the Time for 
Thrombolysis in Emergency Neurological Deﬁcits - Intra-Arterial)11, SWIFT PRIME  
(Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment)12, 
REVASCAT (Endovascular Revascularization With Solitaire Device Versus Best Medical 
Therapy in Anterior Circulation Stroke Within 8 Hours After Symptom Onset in Ischemic 
Stroke)10, and THRACE (Mechanical thrombectomy after intravenous alteplase versus 
alteplase alone after stroke)14 demonstrated the efﬁcacy of EVT versus IV-tPA alone in 
treating patients with acute anterior circulation ischemic stroke.  
All six randomized, controlled trials, showed a beneﬁt for endovascular treatment compared 
with IV t-PA alone regarding functional outcomes. The percentage of patients achieving a 
favorable clinical outcome with EVT varied between 33% and 71%; there was a consistent 
positive difference across all the studies with functional independence (deﬁned as a modiﬁed 
Rankin Scale score of 0 to 2 at 90 days) between the interventional and control arms favoring 
EVT by 14% to 31% (Table 1). The difference between the groups was more pronounced in 
the trials in which penumbral imaging with CT perfusion was used. However, even without 
imaging selection beyond the unenhanced CT, such as in the MR CLEAN and THRACE 
studies, there was a clear beneﬁt in favor of EVT.  
In all studies the intra-cerebral hemorrhage risk in both the interventional and control arms 
ranged from 0% to 7%. The fact that in all the trials EVT carried no higher bleeding risk or 90 
days mortality rate compared with IV t-PA demonstrates that thrombectomy is safe and any 
bleeding risk is caused mainly by thrombolysis. There was an overall trend toward a reduction 
in mortality with EVT. Successful recanalization was deﬁned as a Thrombolysis In Cerebral 
Infarction score of 2b or 3 and varied between 59% and 88%. The trials showed also that the 
likelihood of a good outcome increased with better recanalization.  
Meta-analysis 
A meta-analysis of individual patient data from the five first randomized trials addressed the 
fact that the degree of benefit conferred by endovascular thrombectomy is substantial: for 
every 100 patients treated, 38 will have a less disabled outcome than with best medical 
management and 20 more will achieve functional independence (mRS 0-2) as a result of 
treatment. The number needed to treat for one patient to have reduced disability of at least 1 
point on mRS was 2.69. 
For subgroup analysis of mRS distribution shift at 90 days, there was no evidence of 
heterogeneity of treatment eﬀ ect across any of the pre-speciﬁed variables: age, gender, 
National Institutes of Health Stroke Scale (NIHSS) at admission, site of intracranial 
occlusion, intravenous alteplase received or ineligible,  Alberta Stroke Program Early CT 
Score (ASPECTS), time from onset to randomization, and presence of tandem cervical carotid 
occlusion. The direction of eﬀ ect favored endovascular treatment across all strata, although 
the adjusted ORs for treatment were not signiﬁcant for patients younger than 50 years, those 
with a low ASPECTS or NIHSS score, or in those with an M2 segment thrombus. Eﬀ ects 
favoring intervention were signiﬁcant in several subgroups of special interest, including 
patients older than 80 years, those randomized more than 300 min after symptom onset, and 
those not receiving intravenous t-PA9,16. There was also no evidence of heterogeneity of 
treatment eﬀ ect across the pre-speciﬁed subgroups for achievement of functional 
independence (mRS 0–2) at 90 days.  
The rates of symptomatic intracranial hemorrhage and radiological intracerebral hematoma 
are no higher with endovascular thrombectomy than with best medical therapy alone and 
mortality risk did not significantly differ between groups. No heterogeneity of treatment eﬀect 
was noted for mortality (p interaction=0·33) but rate ratios were rarely signiﬁcant in any of 
the subgroups. Patients older than 80 years assigned to thrombectomy had a slightly reduced 
risk of death assigned to control. 
 
Acute Stroke Therapy: Practical Aspects 
When treating acute stroke, time matters and optimized stroke protocols are necessary in 
order to avoid in-hospital delay and achieve the best possible outcome17. In practice less than 
one-third of the patients meet the goal of a "door-to-needle time" of <60 min18. Therapeutic 
strategy should be designed, executed and monitored to emphasize expeditious assessment 
and treatment.   An on-demand, 24-7-365, stroke reperfusion service is also required 19,20.  
Important features that affect treatment decisions include time of presentation, the patient’s 
clinical status, imaging characteristics, and lab tests. 
 
Time of presentation 
IV t-PA and EVT reperfusion therapies have both been shown to improve patient outcomes. 
However, the time window for treatment with either approach is limited. IV thrombolysis can 
be given up to 4.5 h after stroke onset; additional or primary EVT can be used up to 12 h after 
stroke onset. In anterior circulation strokes, the impact of successful thrombectomy is greater 
in the ﬁrst 3 to 4.5 h after stroke compared with late recanalization after 5 to 8 h21. A meta-
analysis of recent randomized trials showed that in patients who achieved substantial 
reperfusion with endovascular thrombectomy, each 1-hour delay to reperfusion was 
associated with a less favorable degree of disability and less functional independence, but no 
change in mortality22. 
 
Clinical examination  
A neurologic exam should be performed according to the National Institute of Health Stroke 
Scale (NIHSS). Precise and fast assessment of the NIHSS score requires some experience and 
should be practiced under non-acute circumstances. Patients with significant deficits 
manifesting scores between 8 and 20 are more likely to benefit from reperfusion with EVT, 
making them better candidates for treatment. Patients with minor to mild symptoms (NIHSS 
<8) and an existing intracranial large vessel occlusion were not included in the trials. In these 
patients, the decision to perform additional EVT is based on the endovascular specialist’s 
experience and the estimated risk of the procedure20. 
Imaging 
At the minimum a non-contrast CT scan should be performed to rule out intracerebral 
hemorrhage and stroke mimics (e.g., space occupying lesions) (Fig 1). ASPECTS 
quantitatively evaluates the core of ischemia on CT scans. ASPECTS is a topographic scoring 
system that divides the middle cerebral artery (MCA) territory of the brain affected by 
ischemic damage into 10 areas of interest. It is a strong predictor of both functional outcome 
and adverse events following treatment23. In a meta-analysis of the four studies that presented 
stratified ASPECTS data for mRS endovascular stroke treatment improved functional 
independence compared with best medical treatment in patients with high baseline 
ASPECTS24. Mechanical thrombectomy also improved functional independence with 
moderate baseline ASPECTS. There was no evidence of benefit for endovascular stroke 
treatment in patients with low baseline ASPECTS. Overall, these results suggest that patients 
with baseline ASPECTS>6 benefit from endovascular stroke treatment. Clinically, an 
important distinction should be made between low ASPECTS as an indicator of a very poor 
prognosis and any possible treatment eﬀ ect of reperfusion. If the prognosis is extremely poor, 
even a small treatment eﬀ ect might not represent a useful intervention. ASPECTS is 
recommended by the American Society of Neuroradiology, American Heart Association/ 
American Stroke Association, European Stroke Organisation, and the Canadian Stroke Best 
Practice. 
CT angiography confirms the existence of a large vessel occlusion, allows localization of the 
occluded vessel and may facilitate the intervention by obviating the need for cerebral 
angiography of non-target vessels (Fig 2). Moreover, it may identify collateral circulation and 
clot length25.  A post hoc analysis of MR CLEAN neuroimaging data evaluated how the 
collateral status of the target vessel related to clinical outcome. Collaterals were graded on 
baseline CTA with a 4-point scale. This study demonstrated that baseline CTA collateral 
status modified the effect of EVT. The benefit of EVT was robust in patients with good 
collaterals on baseline CTA (Fig 2). Treatment benefit could not be established in patients 
with absent or poor collaterals26. However, in everyday clinical practice collateral status 
assessment on CTA can be prone to interobserver variability. 
In two of the randomized trials (MR CLEAN and TRACE) imaging included mostly 
unenhanced CT scans and CT angiography.  
Assessment of the presence and size of cerebral parenchymal damage guides candidacy for 
intravenous or intra-arterial therapy. If available MR- or CT-perfusion imaging can allow 
identification and quantification of the ischemic penumbra (ischemic, yet viable tissue at risk 
that may be salvaged by timely reperfusion), guiding further therapy, especially in wake-up 
strokes or presentations with onset of symptoms > 6 hours or patients who are within 6 hours 
of symptom onset and have an ASPECTS <6.  
Mobile CT scanners or flat panel CT in the catheterization laboratory and intensive care units 
may accelerate treatment decisions27.  
Lab tests 
Because time is critical, a limited number of essential diagnostic tests are recommended. A 
complete blood count, partial thromboplastin time (PTT), prothrombin time, serum creatinine, 
electrolytes, and glucose level should be obtained upon patient arrival in the emergency 
department. Only the assessment of blood glucose in addition to a head CT scan, must 
precede the initiation of IV rtPA.  To shorten potential delays, portable point of care 
laboratory systems that allow measurement of these parameters at the site of imaging or in the 
emergency department have been shown to be useful17. 
 
Endovascular Procedure 
Thrombectomy devices 
Based on the above recent positive multicenter randomized clinical trials, EVT has undergone 
a revolution. One of the main changes in these positive studies was the utilization of stent 
retriever devices. Stent retrievers are self-expandable stent-like devices that are fully 
retrievable. Therefore, these devices combine the advantages of prompt flow restoration and 
mechanical thrombectomy (Fig 3). The excellent recanalization results with low complication 
rates led to a high rate of favorable clinical outcome, confirming registry data and other 
randomized trials19,28,29. 
However, clinical experience has reported situations that are resistant to stent retriever 
recanalization attempts. These situations include occlusions located in terminal internal 
carotid artery (tICA) and middle cerebral artery (MCA) bifurcation and trifurcation thrombi, 
as well as hard thrombi configuration. For these cases, direct aspiration of the thrombus can 
be used as an alternative technique. The aspiration technique has been an early component 
in the history of mechanical thrombectomy and has been published in a large number of small 
trials and clinical experiences30 (Fig 4). Over the course of time a great effort has been made 
to develop new aspiration devices, including changes in the distal inner diameters of the 
catheter. The main advantages of aspiration technique are the fast procedure time and the high 
rate of favorable clinical outcome if primary aspiration is successful.  For direct thrombus 
aspiration, the most common aspiration catheters that are used are 5-F systems, e.g., the 
Penumbra ACE 64 reperfusion catheter (Penumbra Inc.), which has a 0.064-inch inner lumen 
and is signiﬁcantly larger than the previous generation of aspiration catheters. Aspiration is 
performed with a pump that is capable of maintaining a nearly pure vacuum of 29 inHg (98.2 
kPa). An aspiration catheter with a 0.068" distal inner diameter is already available (ACE 68, 
Penumbra Inc.) for clinical use28.  
 
General anesthesia vs. conscious sedation 
Endovascular thrombectomy is performed under general anesthesia with intubation or under 
conscious sedation. Some interventionalists and stroke physicians prefer general anesthesia 
with intubation, assuming it may be associated with less pain, anxiety, agitation, and 
movement, and lower aspiration risk. Others favor conscious sedation to save time, evoke less 
hemodynamic instability, and risk fewer ventilation-associated complications (sedation). 
Pathophysiological considerations concerning general anesthesia is anesthesia-associated 
hypotension and hypocapnia, the latter potentially causing cerebral vasoconstriction 
influencing the collateral status.  
MR CLEAN investigators have reported that the outcomes of the 79 patients in the 
endovascular group who received general anesthesia were no different from the 267 non-
endovascular control patients, whereas for the 137 endovascular patients who did not receive 
general anesthesia the outcomes were better than for the 267 control patients31. Similar data 
showing worse outcomes in those undergoing general anesthesia as compared to conscious 
sedation for endovascular were reported in a recent meta-analysis of 9 non-randomized 
studies. However, all these studies have selection bias, since general anesthesia was often 
chosen for patients with more severe illness32. 
In contrast, in a single-center trial published recently, 150 randomized patients with acute 
ischemic stroke were to receive either general anesthesia with intubation or conscious 
sedation without intubation during thrombectomy. Early improvement in neurological 
function was not significantly different between treatment groups. Functional independence at 
90 days, as reflected by a modified Rankin Scale score of 0 to 2, was significantly more 
frequent in the general anesthesia group (37%) than in the conscious sedation group (18.2%) 
33. Notable in this study is the low rate of favorable clinical outcome at 90 days with only 
18.2% in the conscious sedation group. Another critical issue of the study was that both 
general anesthesia and conscious sedation were performed by neurologists and not 
anesthesiologists. 
Thus, a lack of clear superiority data between general anesthesia or conscious sedation 
suggests that interventionalists should choose the preferred method based on experience 
pending further studies. 
 
Technique 
With rare exceptions, femoral access is obtained. The radial artery may also be used in cases 
where puncture of the femoral arteries is not possible. To perform an intracranial 
thrombectomy it is necessary to place the long 6-F sheath or the 8-F guide catheter in the 
internal carotid artery (ICA). To place the sheath in the ICA, it is necessary to use a coaxial 
125-cm long catheter over a guidewire. Two catheters can be used, the multipurpose catheter 
for a type I aortic arch conﬁguration and the SIM2 catheter for type II and III aortic arch 
conﬁgurations. 
After placement of the long 6-F sheath in the ICA, if possible in the petrous part, the 
occlusion of the target vessel is veriﬁed angiographically. The target vessel is entered with a 
0.014-inch guidewire and a suitable microcatheter between 0.018 and 0.027 inches. The 
thrombus is crossed with the guidewire, and the microcatheter is placed distal to the 
thrombus. The stent retriever device is advanced to the distal end of the microcatheter. Then 
the microcatheter is removed to deploy the device under fluoroscopy.  The device should 
extend beyond the proximal and distal edges of the thrombus. A control angiogram is 
performed after successful unfolding of the device. The sizes of stent retriever devices range 
from 3.0x15 mm to 6.0x40mm. Stent retriever device selection depends on the size of the 
occluded artery (Fig 3). Typically, a 4- to 4.5-mm device is used for the middle cerebral 
artery (MCA) and a 6.0-mm device for occlusions in the terminal ICA. After a short period of 
time, the device is retrieved with continuous aspiration. If a balloon catheter is used, the 
balloon is inflated before retrieving the thrombectomy device. The procedure is repeated until 
a Thrombolysis In Cerebral Infarction score of 2b or 3 is reached19. 
If aspiration technique is used, the thrombus is crossed with the microwire and 
microcatheter, and the aspiration catheter is placed directly in the proximal part of the 
thrombus. The microwire and the microcatheter are removed. Entrapment of the thrombus is 
indicated by the absence of backflow. The catheter is then retrieved with constant negative 
pressure to avoid loss of thrombus. After each retrieval of clot fragments, the procedure is 
repeated until a TICI score of ≥2 or 3 was reached (Fig 4). 
Another technique is a combination of the two reperfusion systems, deploying the stent 
retriever in the thrombus, then placing the aspiration catheter at the proximal end of the stent 
retriever and pulling back both of them simultaneously under continuous aspiration.   
 
Everyday clinical practice 
The patients included in the randomized trials were carefully selected and the results were 
based on a very efficient workflow. Therefore, an interesting question arises: Can the 
promising results of these trials also be achieved in everyday clinical practice? A 
prospectively obtained database of a high-volume stroke center compared the early clinical 
outcome in patients with anterior circulation large vessel occlusions treated either with 
systemic thrombolysis or EVT with stent retrievers. The analysis in a total of 779 patients 
showed that significantly more patients in the endovascular treatment group than in the 
intravenous thrombolysis group had a favorable early clinical outcome (mRS 0-2 at discharge 
37% vs. 27%, p < 0.01) in everyday clinical practice. Similarly, significantly more patients in 
the EVT group than in the IVT group had an excellent early clinical outcome (mRS 0–1) 
(20% vs. 13%, p < 0.01).  The infarct sizes were significantly smaller after endovascular 
treatment than after intravenous thrombolysis, whereas the symptomatic intracranial 
hemorrhages rate and in-hospital mortality were comparable between both treatment groups34.  
Costs 
Stroke itself is an expensive disease in terms of its societal, personal, and financial impact. 
Rationalization concerning the clinical value and effectiveness of thrombectomy is guided by 
information regarding the benefits, risks, and associated costs. Recent cost-effectiveness 
analysis based on the UK National Health Service shows that although the upfront costs of 
thrombectomy are high, the potential reduction in morbidity can result in savings downstream 
both in the hospital and in the community setting, resulting in a significant reduction in the 
overall economic burden of stroke35.  
Conclusion 
Routine endovascular thrombectomy has been shown to provide excellent outcomes for 
patients with proximal anterior circulation occlusions. This procedure reduces disability and 
benefits are seen across a wide range of age and initial stroke severity. Under optimal 
conditions, this treatment should be available to stroke patients at most locations 24/7, similar 
primary percutaneous coronary interventions for patients with acute ST-segment elevation 
myocardial infarctions. To accomplish this, a sufficient number of centers with acute stroke 
management systems in place and an adequate number of well-trained physicians capable of 
performing EVT for stroke are needed.  
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